Download Free Journal Of Contraception Book in PDF and EPUB Free Download. You can read online Journal Of Contraception and write the review.

The development, manufacturing, and use of contraceptive methods from the late nineteenth century to the present, viewed from the perspective of reproductive justice. The beginning of the modern contraceptive era began in 1882, when Dr. Aletta Jacobs opened the first birth control clinic in Amsterdam. The founding of this facility, and the clinical provision of contraception that it enabled, marked the moment when physicians started to take the prevention of pregnancy seriously as a medical concern. In this volume in the MIT Press Essential Knowledge series, Donna Drucker traces the history of modern contraception, outlining the development, manufacturing, and use of contraceptive methods from the opening of Dr. Jacobs's clinic to the present. Drucker approaches the subject from the perspective of reproductive justice: the right to have a child, the right not to have a child, and the right to parent children safely and healthily. Drucker describes contraceptive methods available before the pill, including the diaphragm (dispensed at the Jacobs clinic) and condom, spermicidal jellies, and periodic abstinences. She looks at the development and dissemination of the pill and its chemical descendants; describes technological developments in such non-hormonal contraceptives as the cervical cap and timing methods (including the “rhythm method” favored by the Roman Catholic church); and explains the concept of reproductive justice. Finally, Drucker considers the future of contraception—the adaptations of existing methods, new forms of distribution, and ongoing efforts needed to support contraceptive access worldwide.
Se estudian las consecuencias sanitarias de los diferentes patrones reproductivos en la salud de la mujer y de los niños. Tambien se evaluan el riesgo y los beneficios de los diferentes metodos anticonceptivos, aunque algunos de los datos en los que se basa son de paises desarrollados, el nucleo central del informe son los paises en desarrollo.
The "contraceptive revolution" of the 1960s and 1970s introduced totally new contraceptive options and launched an era of research and product development. Yet by the late 1980s, conditions had changed and improvements in contraceptive products, while very important in relation to improved oral contraceptives, IUDs, implants, and injectables, had become primarily incremental. Is it time for a second contraceptive revolution and how might it happen? Contraceptive Research and Development explores the frontiers of science where the contraceptives of the future are likely to be found and lays out criteria for deciding where to make the next R&D investments. The book comprehensively examines today's contraceptive needs, identifies "niches" in those needs that seem most readily translatable into market terms, and scrutinizes issues that shape the market: method side effects and contraceptive failure, the challenge of HIV/AIDS and other sexually transmitted diseases, and the implications of the "women's agenda." Contraceptive Research and Development analyzes the response of the pharmaceutical industry to current dynamics in regulation, liability, public opinion, and the economics of the health sector and offers an integrated set of recommendations for public- and private-sector action to meet a whole new generation of demand.
This document is one of two evidence-based cornerstones of the World Health Organization's (WHO) new initiative to develop and implement evidence-based guidelines for family planning. The first cornerstone, the Medical eligibility criteria for contraceptive use (third edition) published in 2004, provides guidance for who can use contraceptive methods safely. This document, the Selected practice recommendations for contraceptive use (second edition), provides guidance for how to use contraceptive methods safely and effectively once they are deemed to be medically appropriate. The recommendations contained in this document are the product of a process that culminated in an expert Working Group meeting held at the World Health Organization, Geneva, 13-16 April 2004.
I opened my series editor manuscript of The Handbook of Contraception: A Guide for Practical Management, edited by Drs. Donna Shoupe and Siri Kjos, on a tiny plane on the way to giving a lecture in Albany, NY. I expected to peruse the ma- script, and found that I could not put it down. The Handbook of Contraception: A Guide for Practical Management is an incredibly informative and enjoyable read. In keeping with the objective of this series for primary care clinicians, there is a quality in this title that is uncommon among medical textbooks. The chapters of this book are written with extraordinary intelligence and und- standing, and with attention to practical considerations in the selection and mana- ment of contraceptive options. The authors have reviewed the science behind contraception, including the chemical structure and effects of hormonal contraception, physiology of contraception, efficacy rates, and side effects, as well as the practical considerations that are relevant in helping patients choose between different cont- ceptive options. They do this with a clarity of language and intent that lets the book cover with sufficient detail the full range of questions that any primary care clinician will have regarding any of the traditional or new contraceptive options. Also included in each chapter is a section on “counseling tips,” which explicitly answers many of the questions that clinicians and their patients often have when discussing contraceptive options. For a book so useful and well done, the editors and authors deserve our thanks.
This text traces the history of contraception and abortifacients from ancient Egypt to the 17th century, and discusses the scientific merit of the ancient remedies and why this knowledge about fertility control was gradually lost over the course of the Middle Ages.
Drawing from a wide range of private and public sources, examines how American families gradually found access to taboo information and products for controlling the size of their families from the 1830s to the 1890s when a puritan backlash made most of it illegal. Emphasizes the importance of two shadowy networks, medical practitioners known as Thomsonians and water-curists, and iconoclastic freethinkers.
Practical, authoritative, and up-to-date,Speroff & Darney’s Clinical Guide to Contraception, 6th Edition, provides concise coverage of all of today’s available contraceptive options. Under the leadership of new editors Jeffrey T. Jensen, MD, MPH, and Mitchell Creinin, MD, this well-regarded clinical reference remains a thorough, evidence-based, and readable resource for OB/GYNs, family planning specialists, primary care providers, and other healthcare providers.
Evaluates evidence for an increased risk of cancer in women using combined oral contraceptives, progestogen-only hormonal contraceptives, post-menopausal estrogen therapy, and post-menopausal estrogen-progestogen therapy. Although the carcinogenicity of these preparations has been extensively investigated, the book stresses the many complex methodological issues that must be considered when interpreting findings and weighing results. Evidence of an association between use of these preparations and positive effects on health, including a reduced risk of some cancers, is also critically assessed. The first and most extensive monograph evaluates evidence of an association between the use of combined oral contraceptives and cancer at nine sites. Concerning breast cancer, the evaluation concludes that, even if the association is causal, the excess risk for breast cancer associated with patterns of use that are typical today is very small. Studies of predominantly high-dose preparations found an increased risk of hepatocellular carcinoma in the absence of hepatitis viruses. Citing these findings, the evaluation concludes that there is sufficient evidence in humans for the carcinogenicity of combined oral contraceptives. The evaluation also found sufficient evidence for the carcinogenicity of some, but not all, combined preparations in animals. Combined oral contraceptives were classified as carcinogenic to humans. The evaluation also cites conclusive evidence that these agents have a protective effect against cancers of the ovary and endometrium. Progestogen-only contraceptives are evaluated in the second monograph, which considers the association with cancer at six sites. The evaluation found no evidence of an increased risk for breast cancer. Although the evaluation found sufficient evidence in animals for the carcinogenicity of medroxyprogesterone acetate, evidence for the carcinogenicity of progestogen-only contraceptives in humans was judged inadequate. Progestogen-only contraceptives were classified as possibly carcinogenic to humans. The third monograph, on post-menopausal estrogen therapy, considers evidence of an association with cancer at eight sites. Findings from a large number of epidemiological studies indicate a small increase in the risk of breast cancer in women who have used these preparations for five years or more. Studies consistently show an association between use of post-menopausal estrogen therapy and an increased risk for endometrial cancer. Data on the association with other cancers were either inconclusive or suggested no effect on risk. The evaluation concludes that post-menopausal estrogen therapy is carcinogenic to humans. The final monograph evaluates the association between the use of post-menopausal estrogen-progestogen therapy and cancer at four sites. The evaluation of limited data on breast cancer found an increased relative risk observed with long-term use. Data were judged insufficient to assess the effects of past use and of different progestogen compounds, doses, and treatment schedules. For endometrial cancer, the evaluation found an increase in risk relative to non-users when the progestogen was added to the cycle for 10 days or fewer. Post-menopausal estrogen-progestogen therapy was classified as possibly carcinogenic to humans. Concerning post-menopausal therapy in general, the book notes that evidence of carcinogenic risks must be placed in perspective of potential benefits. The prevention of osteoporotic fractures is cited as the best-established benefit. Evidence also suggests that estrogen prevents heart disease and may prevent memory loss and dementia.
This narrative history of one of the most far-reaching social movements in the 20th century shows how it defied the law and made the use of contraception an acceptable social practice—and a necessary component of modern healthcare. A History of the Birth Control Movement in America tells the extraordinary story of a group of reformers dedicated to making contraception legal, accessible, and acceptable. The engrossing tale details how Margaret Sanger's campaign beginning in 1914 to challenge anti-obscenity laws criminalizing the distribution of contraceptive information grew into one of the most far-reaching social reform movements in American history. The book opens with a discussion of the history of birth control methods and the criminalization of contraception and abortion in the 19th century. Its core, however, is an exciting narrative of the campaign in the 20th century, vividly recalling the arrests and indictments, banned publications, imprisonments, confiscations, clinic raids, mass meetings, and courtroom dramas that publicized the cause across the nation. Attention is paid to the movement's thorny alliances with medicine and eugenics and especially to its success in precipitating a profound shift in sexual attitudes that turned the use of contraception into an acceptable social and medical practice. Finally, the birth control movement is linked to court-won privacy protections and the present-day movement for reproductive rights.